Sheldon Litwin to Stroke Volume
This is a "connection" page, showing publications Sheldon Litwin has written about Stroke Volume.
Connection Strength
1.682
-
Pharmacologic Weight Loss for Heart Failure With Preserved Ejection Fraction: Getting to the Core of the Problem. Circ Heart Fail. 2021 09; 14(9):e008554.
Score: 0.637
-
Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 11 02; 10(21):e022930.
Score: 0.161
-
The Vexing Problem of HFpEF?Therapeutics: Inching Toward Success. JACC Heart Fail. 2021 05; 9(5):371-373.
Score: 0.155
-
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. Circulation. 2018 01 23; 137(4):364-375.
Score: 0.122
-
Cardiac remodeling in obesity: time for a new paradigm. JACC Cardiovasc Imaging. 2010 Mar; 3(3):275-7.
Score: 0.072
-
The associations between tricuspid annular plane systolic excursion (TAPSE), ventricular dyssynchrony, and ventricular interaction in heart failure patients. Eur J Echocardiogr. 2008 Nov; 9(6):766-71.
Score: 0.063
-
The growing problem of obesity and the heart: the plot "thickens". J Am Coll Cardiol. 2006 Feb 07; 47(3):617-9.
Score: 0.054
-
Close coupling of systolic and diastolic function: combined assessment provides superior prediction of exercise capacity. J Card Fail. 2005 Sep; 11(7):516-22.
Score: 0.052
-
Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022 11 01; 43(41):4406-4417.
Score: 0.043
-
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort. Eur J Heart Fail. 2022 08; 24(8):1410-1414.
Score: 0.042
-
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022 03 19; 399(10330):1130-1140.
Score: 0.041
-
Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction. ESC Heart Fail. 2022 02; 9(1):186-195.
Score: 0.040
-
Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. J Am Heart Assoc. 2020 09; 9(17):e016760.
Score: 0.037
-
Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 11 26; 74(21):2539-2550.
Score: 0.035
-
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). Am J Cardiol. 2019 12 15; 124(12):1912-1917.
Score: 0.035
-
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 10 01; 3(10):968-977.
Score: 0.032
-
Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice. Am J Physiol Renal Physiol. 2010 Mar; 298(3):F754-62.
Score: 0.018
-
Effects of different pacing modes on left ventricular relaxation in closed-chest dogs. Pacing Clin Electrophysiol. 1989 Jul; 12(7 Pt 1):1070-6.
Score: 0.017
-
Scatter in repolarization timing predicts clinical events in post-myocardial infarction patients. Heart Rhythm. 2008 Feb; 5(2):208-14.
Score: 0.015
-
Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. J Control Release. 2003 Dec 05; 93(2):175-81.
Score: 0.012